|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCDC51 |
Gene summary for CCDC51 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCDC51 | Gene ID | 79714 |
| Gene name | coiled-coil domain containing 51 | |
| Gene Alias | MITOK | |
| Cytomap | 3p21.31 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q96ER9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79714 | CCDC51 | LZE4T | Human | Esophagus | ESCC | 1.71e-08 | 2.52e-01 | 0.0811 |
| 79714 | CCDC51 | LZE7T | Human | Esophagus | ESCC | 1.56e-02 | 2.04e-01 | 0.0667 |
| 79714 | CCDC51 | LZE21T | Human | Esophagus | ESCC | 4.59e-02 | 1.55e-01 | 0.0655 |
| 79714 | CCDC51 | P1T-E | Human | Esophagus | ESCC | 9.91e-03 | 2.13e-01 | 0.0875 |
| 79714 | CCDC51 | P2T-E | Human | Esophagus | ESCC | 1.43e-05 | 1.14e-01 | 0.1177 |
| 79714 | CCDC51 | P4T-E | Human | Esophagus | ESCC | 1.17e-19 | 4.53e-01 | 0.1323 |
| 79714 | CCDC51 | P5T-E | Human | Esophagus | ESCC | 1.74e-11 | 2.45e-01 | 0.1327 |
| 79714 | CCDC51 | P8T-E | Human | Esophagus | ESCC | 3.65e-12 | 1.16e-01 | 0.0889 |
| 79714 | CCDC51 | P9T-E | Human | Esophagus | ESCC | 2.79e-19 | 4.13e-01 | 0.1131 |
| 79714 | CCDC51 | P10T-E | Human | Esophagus | ESCC | 1.47e-11 | 2.65e-01 | 0.116 |
| 79714 | CCDC51 | P12T-E | Human | Esophagus | ESCC | 6.30e-30 | 6.69e-01 | 0.1122 |
| 79714 | CCDC51 | P15T-E | Human | Esophagus | ESCC | 2.35e-09 | 2.25e-01 | 0.1149 |
| 79714 | CCDC51 | P16T-E | Human | Esophagus | ESCC | 1.38e-11 | 2.25e-01 | 0.1153 |
| 79714 | CCDC51 | P17T-E | Human | Esophagus | ESCC | 4.92e-07 | 2.87e-01 | 0.1278 |
| 79714 | CCDC51 | P20T-E | Human | Esophagus | ESCC | 1.85e-07 | 1.62e-01 | 0.1124 |
| 79714 | CCDC51 | P21T-E | Human | Esophagus | ESCC | 6.88e-14 | 3.31e-01 | 0.1617 |
| 79714 | CCDC51 | P22T-E | Human | Esophagus | ESCC | 3.34e-23 | 5.25e-01 | 0.1236 |
| 79714 | CCDC51 | P23T-E | Human | Esophagus | ESCC | 2.12e-14 | 3.98e-01 | 0.108 |
| 79714 | CCDC51 | P24T-E | Human | Esophagus | ESCC | 4.54e-12 | 3.07e-01 | 0.1287 |
| 79714 | CCDC51 | P26T-E | Human | Esophagus | ESCC | 1.68e-27 | 6.41e-01 | 0.1276 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCDC51 | SNV | Missense_Mutation | c.1195G>A | p.Ala399Thr | p.A399T | Q96ER9 | protein_coding | tolerated(0.13) | possibly_damaging(0.465) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CCDC51 | SNV | Missense_Mutation | c.603N>T | p.Lys201Asn | p.K201N | Q96ER9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| CCDC51 | SNV | Missense_Mutation | c.755C>T | p.Ala252Val | p.A252V | Q96ER9 | protein_coding | tolerated(0.09) | probably_damaging(0.958) | TCGA-D5-6927-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| CCDC51 | SNV | Missense_Mutation | c.84N>T | p.Arg28Ser | p.R28S | Q96ER9 | protein_coding | tolerated_low_confidence(0.38) | benign(0.017) | TCGA-F4-6807-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | CR | |
| CCDC51 | SNV | Missense_Mutation | c.646N>A | p.Val216Met | p.V216M | Q96ER9 | protein_coding | deleterious(0) | possibly_damaging(0.892) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CCDC51 | SNV | Missense_Mutation | c.793N>A | p.Leu265Ile | p.L265I | Q96ER9 | protein_coding | tolerated(0.2) | benign(0.203) | TCGA-QG-A5Z2-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| CCDC51 | SNV | Missense_Mutation | novel | c.596N>T | p.Arg199Met | p.R199M | Q96ER9 | protein_coding | deleterious(0) | probably_damaging(0.939) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| CCDC51 | SNV | Missense_Mutation | novel | c.905N>T | p.Ala302Val | p.A302V | Q96ER9 | protein_coding | deleterious(0.03) | benign(0.178) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CCDC51 | SNV | Missense_Mutation | novel | c.878N>G | p.Asp293Gly | p.D293G | Q96ER9 | protein_coding | tolerated(0.37) | benign(0) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CCDC51 | SNV | Missense_Mutation | novel | c.473N>C | p.Leu158Pro | p.L158P | Q96ER9 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |